Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Total and cardiovascular mortality risk according to KDIGO guidelines classifica...
Journal Information
Vol. 153. Issue 7.
Pages 263-269 (October 2019)
Share
Share
Download PDF
More article options
Visits
302
Vol. 153. Issue 7.
Pages 263-269 (October 2019)
Original article
Total and cardiovascular mortality risk according to KDIGO guidelines classification in type 2 diabetic patients
Riesgo de mortalidad total y cardiovascular según la clasificación propuesta por las guías KDIGO en pacientes con diabetes tipo 2
Visits
302
Ana Lidia Medrano Navarroa,
Corresponding author
analidia.medrano@gmail.com

Corresponding author.
, Alicia Justel Enríquezb, Javier Alameda Serranoc, Yolanda Blasco Lamarcad, Daniel Sáenz Abade, José Antonio Gimeno Ornad,e
a Unidad de Endocrinología y Nutrición, Hospital de Barbastro, Barbastro, Huesca, Spain
b Servicio de Endocrinología y Nutrición, Hospital de Huelva, Huelva, Spain
c Servicio de Cardiología, Hospital Royo Villanova, Zaragoza, Spain
d Servicio de Endocrinología y Nutrición, Hospital Clínico Lozano Blesa, Zaragoza, Spain
e Instituto de Investigación Sanitaria de Aragón, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (4)
Table 1. Percentage of patients in each GFR and UAE combined category.
Table 2. Characteristics of patients according to KDIGO risk classification at the time of inclusion.
Table 3. Total and cardiovascular mortality rates according to the baseline characteristics of the patients. Rate comparison using log rank test.
Table 4. Risk of total and cardiovascular mortality depending on the baseline characteristics of the patients.
Show moreShow less
Abstract
Background and aims

Our aim was to assess the usefulness of KDIGO 2012 risk classification to predict total and cardiovascular mortality in type 2 diabetes mellitus (DM2).

Material and methods

Prospective cohort study that included DM2 patients. Clinical end-points were total and cardiovascular mortality. The main predictive variable was KDIGO risk classification, which is a combination of urinary albumin excretion and glomerular filtration rate. The predictive value was evaluated by the integrated discrimination improvement (IDI) index.

Results

453 patients (39.3% males, aged 64.9 [SD 9.3] and with a mean diabetes duration of 10.4 [SD 7.5] years) were included. During a median follow-up of 13 years, mortality rates per 1000patients/year (26.5 vs. 45.1 vs. 79.2 vs. 109.8; p<0.001) and cardiovascular mortality (8.1 vs. 17.4 vs. 24.7 vs. 57.5; p<0.001) were progressively increased in successive KDIGO categories. In the multivariate analysis, there was also a progressive increase of mortality risk (HR[moderate risk]=1.29; HR[high risk]=1.83; HR[very high risk]=2.15; p=0.016) and cardiovascular mortality risk (HR[moderate risk]=1.73; HR[high risk]=2.27; HR[very high risk]=4.22; p=0.007) in the successive categories. KDIGO classification was able to improve the mortality risk prediction (IDI=0.00888; p=0.047) and cardiovascular mortality risk prediction (IDI=0.01813; p=0.035).

Conclusions

KDIGO risk classification can effectively stratify total and cardiovascular mortality risk in DM2 patients.

Keywords:
Diabetes mellitus
Survival
Prognosis
Resumen
Antecedentes y objetivo

El objetivo del estudio fue comprobar la validez de la clasificación de riesgo KDIGO 2012 para predecir mortalidad total (MT) y cardiovascular (MCV) en diabetes mellitus tipo 2 (DM2).

Materiales y métodos

Estudio de cohortes prospectivo incluyendo pacientes con DM2. Los puntos finales clínicos fueron MT y MCV. La principal variable predictora fue la clasificación KDIGO, una variable que recoge 4 niveles de riesgo en dependencia de una combinación de la tasa de filtración glomerular y la excreción de albúmina urinaria. La evaluación del poder predictivo se realizó con el índice de mejora de discriminación integrada (IDI).

Resultados

Se incluyeron 453 pacientes (39,3% varones, edad 64,9 [DE 9,3] años y evolución de DM2 de 10,4 [DE 7,5] años). Durante una mediana de 13 años de seguimiento, hubo incremento significativo de la tasa/1000 pacientes-año de MT (26,5 vs. 45,1 vs. 79,2 vs. 109,8; p<0,001) y de MCV (8,1 vs. 17,4 vs. 24,7 vs. 57,5; p<0,001) en las sucesivas categorías de riesgo KDIGO. En análisis multivariante también hubo incremento de riesgo de MT (HR[riesgo moderado]=1,29; HR[riesgo alto]=1,83; HR[riesgo muy alto]=2,15; p=0,016) y MCV (HR[riesgo moderado]=1,73; HR[riesgo alto]=2,27; HR[riesgo muy alto]=4,22; p=0,007) en las sucesivas categorías. La clasificación KDIGO mejoró la predicción de MT (IDI=0,00888; p=0,047) y MCV (IDI=0,01813; p=0,035).

Conclusiones

La clasificación de riesgo según guías KDIGO 2012 puede estratificar eficazmente el riesgo de MT y MCV en pacientes con DM2.

Palabras clave:
Diabetes mellitus
Supervivencia
Pronóstico

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos